Acarix AB (FRA:7AC) FFO


FRA:7AC Acarix AB FRA:7AC
48 GF Score
Price €0.02
GF Value €0.01
! 1 Warning Sign
View Full Analysis

What is Acarix AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:7AC
48GF Score
Acarix AB FRA:7AC
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Acarix AB (FRA:7AC) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of €0.02 is trading 68% above its estimated GF Value™ of €0.01.

Key valuation signals for FRA:7AC:

  • FFO:
  • GF Value™: €0.01 vs. price of €0.02 (68% above fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the FRA:7AC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACIXF:USAACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
48GF Score

Get the complete analysis for FRA:7AC

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.01
GF Value